Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Illumina Inc (ILMN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 24,955,854
  • Shares Outstanding, K 146,300
  • Annual Sales, $ 2,398 M
  • Annual Income, $ 463 M
  • 36-Month Beta 0.82
  • Price/Sales 10.23
  • Price/Cash Flow 36.56
  • Price/Book 10.85

Price Performance

See More
Period Period Low Period High Performance
1-Month
158.02 +7.95%
on 03/16/17
171.98 -0.81%
on 03/24/17
+10.58 (+6.61%)
since 02/24/17
3-Month
127.09 +34.22%
on 12/28/16
171.98 -0.81%
on 03/24/17
+41.83 (+32.49%)
since 12/23/16
52-Week
119.37 +42.90%
on 12/07/16
186.88 -8.72%
on 10/06/16
+15.24 (+9.81%)
since 03/24/16

Most Recent Stories

More News
SmarTrend Watching for Potential Pullback in Shares of Illumina After 1.22% Gain

Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $162.57 to a high of $165.80. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of $164.88...

ILMN : 170.58 (+1.72%)
CORRECTING and REPLACING Munich Leukemia Laboratory Selects IBM Watson and Illumina for Research Collaboration to Advance Diagnostics and Develop Personalized Treatment Tools for Leukemia & Lymphoma

Please replace the release with the following corrected version due to multiple revisions.

IBM : 173.83 (-0.57%)
ILMN : 170.58 (+1.72%)
Munich Leukemia Laboratory Selects IBM Watson and Illumina for Research Collaboration to Improve Diagnostics and Develop Personalized Treatment Tools for Leukemia & Lymphoma

Munich Leukemia Laboratory (MLL), a state-of-the-art leukemia and lymphoma diagnostic and research laboratory based in Munich, has teamed up with IBM (NYSE: IBM) and Illumina, Inc....

IBM : 173.83 (-0.57%)
ILMN : 170.58 (+1.72%)
OPKO Subsidiary GenPath Women's Health Announces the Availability of ClariTest(TM)

OPKO Health, Inc. (NASDAQ:OPK) announces that GenPath Women's Health, a business unit of OPKO Health subsidiary BioReference Laboratories, will offer ClariTest(TM), a non-invasive prenatal test (NIPT)...

ILMN : 170.58 (+1.72%)
OPK : 7.85 (+2.61%)
OPKO Health's GeneDx Announces Participation in Illumina's iHope Program on International Rare Disease Day

OPKO Health, Inc. (NASDAQ:OPK), today announces that GeneDx, a subsidiary of OPKO Health, is proud to participate as a founding member in Illumina Inc.'s (NASDAQ:ILMN) iHope Network on International Rare...

ILMN : 170.58 (+1.72%)
OPK : 7.85 (+2.61%)
Illumina Announces the iHope Network, an Expansion of Its iHope Philanthropic Clinical Whole Genome Sequencing Program

Illumina, Inc. (NASDAQ:ILMN) today announced the launch of the iHope Network, a consortium of member institutions who have committed to providing clinical whole genome sequencing (cWGS)...

ILMN : 170.58 (+1.72%)
Illumina Set to Possibly Pullback After Yesterday's Rally of 2.81%

Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $161.27 to a high of $164.57. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $163.40...

ILMN : 170.58 (+1.72%)
SmarTrend Watching for Potential Pullback in Shares of Illumina After 2.81% Gain

Illumina (NASDAQ:ILMN) traded in a range yesterday that spanned from a low of $161.27 to a high of $164.57. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $163.40...

ILMN : 170.58 (+1.72%)
Bio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results

HERCULES, CA--(Marketwired - Feb 23, 2017) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced financial...

ILMN : 170.58 (+1.72%)
BIO.B : 197.05 (unch)
BIO : 200.41 (+0.11%)
Bio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results

HERCULES, CA--(Marketwired - Feb 23, 2017) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced financial...

ILMN : 170.58 (+1.72%)
BIO.B : 197.05 (unch)
BIO : 200.41 (+0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company's tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing...

See More

Support & Resistance

2nd Resistance Point 174.29
1st Resistance Point 172.43
Last Price 170.58
1st Support Level 168.27
2nd Support Level 165.97

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.